Reported dose, route, timing, frequency, duration and reconstitution for 60 compounds, indexed by research area. Every row names the source that reports it. Select any of them to assemble a schedule you can print or mail to yourself.
For in-vitro research use only · not for human consumption of any kind. Figures on this page are reproduced from the reference library this site syncs, each row named to the source that reports it. Peppersite does not recommend an amount for any compound, and nothing here has been checked against the studies it derives from.
More is not better. Peptide signalling is dose-dependent, time-sensitive, and goal-specific, and the same compound at the same amount does different things on different schedules.
| Compound | Reported dose | Route | Frequency | Vial · reconstitution | Reported by |
|---|---|---|---|---|---|
5-Amino-1MQ Recovery | Standard: 100 mg once daily · Low: 50 mg once daily · High: 150 mg once daily | oral | once daily8 to 12 weeks on, 4 to 6 weeks off | Reconstitute each vial with 3.0 mL bacteriostatic (BAC) water for ~16.7 mg/mL; 2 vials = ~6 mL total. (Subcutaneous form; the compound is also taken orally.) | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: 4 to 7 hours. The most common research community target dose is 100 mg once daily. |
Advanced Recomp Stack Body Composition · Metabolic Health · Recovery · Performance | Retatrutide: 2 mg/week (initiation, weeks 1-4) escalating to 12 mg/week (maximum, weeks 17-20+); CJC-1295 (No DAC): 100-200 mcg, 1-2x daily; Ipamorelin: 100-200 mcg, 1-2x daily | subcutaneous | Retatrutide: once weekly; CJC-1295 and ipamorelin: 1-2x daily (5-on / 2-off rhythm)Standard cycle 12-16 weeks; Extended cycle 16-24 weeks; Continuous retatrutide + cycled CJC/Ipa (12 weeks on / 4 weeks off). CJC/Ipa cycled 12 weeks on / 4 weeks off; retatrutide can continue. | Retatrutide: 5 mg vial + 1 mL BAC water = 5 mg/mL; 10 mg vial + 2 mL BAC water = 5 mg/mL; 10 mg vial + 1 mL BAC water = 10 mg/mL; 20 mg vial + 2 mL BAC water = 10 mg/mL. Volumes over 1.0 mL need a larger syringe or a split injection at two sites. CJC-1295 (No DAC): 2 mg vial + 1 mL BAC water = 2,000 mcg/mL; 5 mg vial + 2 mL BAC water = 2,500 mcg/mL; 5 mg vial + 2.5 mL BAC water = 2,000 mcg/mL. Ipamorelin: same math as CJC-1295. Pre-blended CJC/Ipa combo vial (10 mg = 5 mg CJC + 5 mg ipamorelin): reconstitute with 2 mL BAC water for 2,500 mcg/mL per peptide; 8 units (0.08 mL) = ~200 mcg of each. Label every vial with compound name, concentration, and reconstitution date. Retatrutide is dosed in mg; CJC/Ipa in mcg, a 1,000x difference. Use U-100 insulin syringes. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
AOD-9604 Metabolic Health · Body Composition · Recovery | Standard: 300-500 mcg/day · Low: 300 mcg · High: 500 mcg | Subcutaneous injection | daily12-24 weeks · Cycle context Phase 2 protocols ran 12-24 weeks. | 3.0 mL bacteriostatic water for a 5 mg vial | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Common research dose is 300-500 mcg/day. |
| 300 mcg SC daily (commonly AM, fasted) | subcutaneous | once daily8-12 weeks · 8-12 week cycles | Commonly 2 mg or 5 mg vialsReconstitute with bacteriostatic water | Commonly published practitioner dosing range - provider confirmation required. | |
| 250-300 mcg | subcutaneous or oral | Once daily8-12 weeks | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Referenced at 250-500 mcg once daily, up to 500 mcg-1 mg for aggressive fat loss protocols. Fasted morning administration cited. Noticeable results reported within 4-6 weeks. | subcutaneous | Once dailyMorning, fasted, before eating · 12 weeks on followed by a short break to prevent desensitization | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
ARA-290 Recovery | 4 mg | subcutaneous or intranasal or oral | Once daily28 days | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). |
BPC-157 Tissue Repair · Soft Tissue Recovery · Tendon/Ligament Recovery · Gut Health · Injury Recovery · Recovery | Standard: 250 mcg twice daily · Low: 250 mcg once daily · High: 500 mcg twice daily | Subcutaneous injection | Twice daily4-6 weeks · Standard | 2 mL BAC water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: under 30 minutes. The standard dosing for BPC-157 is 250 mcg twice daily. |
| 250-500 mcg | subcutaneous or oral or topical | Twice daily (morning and evening)4-6 weeks | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| 250-500 mcg once or twice daily | subcutaneous | once or twice daily4-8 weeks · 4-8 week cycles, may repeat after a break | Commonly supplied as 5 mg or 10 mg vialsReconstitute lyophilized powder with bacteriostatic water; refrigerate after mixing | Commonly published practitioner dosing range - provider confirmation required. | |
| Referenced at 200-500 mcg (0.2-0.5 mg) daily overall; recovery contexts cite 200-400 mcg once or twice daily, commonly right after training. Oral form referenced as viable for gut-focused use. | subcutaneous, intramuscular near injury, or oral | 1-2x dailyMorning for systemic or gut focus; post-workout for tissue repair; before bed for overnight healing · On-cycle 4-6 weeks, off-cycle 1-2 months | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
Cagrilintide Recovery | Standard: 2.4 mg/week · Low: 0.25 mg/week · High: 4.5 mg/week | Subcutaneous injection | once weekly16 weeks | BAC water added per vial; concentration depends on volume chosen. | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: About 159 to 195 hours(~7 to 8 days). Cagrilintide is dosed starting at 0.25 mg once weekly, escalating to 2.4 mg weekly. |
Cagrilintide / Retatrutide Metabolic Health · Body Composition · Weight Management · Appetite Regulation | Retatrutide 12 mg/week + Cagrilintide 2.4 mg/week (maintenance); pre-blend most common as 12.5 mg retatrutide + 2.5 mg cagrilintide per vial | Subcutaneous | Once weekly24-week ramp + open-ended maintenance; community: 16-24 weeks on, 4-8 weeks off | Pre-blend (15 mg vial: 12.5 mg retatrutide + 2.5 mg cagrilintide): add 2.5 mL bacteriostatic water (BAC water) slowly down the vial wall; resulting concentration is 5.0 mg/mL retatrutide + 1.0 mg/mL cagrilintide (6.0 mg/mL total blend). Both compounds use U-100 insulin syringes. BAC water is added slowly down the vial wall. Separate vials each use 1-2 mL BAC water per vial. Reconstituted vials are stable for 28-30 days at 2-8 °C. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
Cagrilintide / Tirzepatide Metabolic Health · Body Composition · Weight Management · Appetite Regulation | Tirzepatide 15.0 mg/week + Cagrilintide 2.4 mg/week (maintenance); sub-maximal example: tirzepatide 10 mg + cagrilintide 1.2 mg | Subcutaneous | Once weekly24-week ramp + open-ended maintenance; or stabilize tirzepatide at 10-15 mg then add cagrilintide for 12+ weeks; or sub-maximal combination as needed | Each vial is reconstituted separately using bacteriostatic water (BAC water). Tirzepatide: 5 mg vial + 1.0 mL BAC = 5 mg/mL; 10 mg vial + 2.0 mL BAC = 5 mg/mL; 10 mg vial + 1.0 mL BAC = 10 mg/mL; 30 mg vial + 3.0 mL BAC = 10 mg/mL. Cagrilintide: 5 mg vial + 2.0 mL BAC = 2.5 mg/mL; 10 mg vial + 2.0 mL BAC = 5.0 mg/mL; 10 mg vial + 1.0 mL BAC = 10.0 mg/mL. Cagrilintide is sensitive, inject BAC water down the vial wall and swirl gently; do not shake (amyloid fibril risk); discard cloudy solution. Label every vial with compound name, concentration, and reconstitution date. Both compounds are stable 28-30 days at 2-8 °C once reconstituted. Standard steps: let vial and BAC water reach room temperature (~10-15 minutes); swab both vial stoppers with alcohol. Do not mix the two compounds in one syringe. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
CagriSema Metabolic Health · Body Composition · Weight Management · Appetite Regulation | cagrilintide 2.4 mg + semaglutide 2.4 mg | Subcutaneous | Once weeklyREDEFINE trials ran 68 weeks; research cycles are commonly 12-24 weeks; short investigative cycles 8-12 weeks. | 1. Wash your hands and lay out a clean work surface. 2. Wipe the rubber stopper of each vial with an alcohol swab and let it dry. 3. Draw the planned BAC water volume into a fresh syringe. 4. Inject the BAC water down the inside wall of the peptide vial, do not spray directly onto the lyophilized powder. 5. Swirl gently until the powder is fully dissolved. Do not shake. 6. Label the vial with the date of reconstitution and the concentration. 7. Refrigerate at 36-46°F (2-8°C) and use within the supplier-specified stability window. For pre-blended vials: BAC water volume is dictated by the vial concentration printed on the COA, there is no universal default for a fixed-dose combination, so verify the supplier's spec before reconstituting. Illustrative examples: 20 mg vial + 2.0 mL BAC water = 10 mg/mL (0.48 mL = 48 units U-100 per weekly maintenance draw); 20 mg vial + 2.5 mL BAC water = 8 mg/mL (0.60 mL = 60 units U-100); 20 mg vial + 3.0 mL BAC water = 6.67 mg/mL (0.72 mL = 72 units U-100). For separate vials: reconstitute each compound independently; e.g. 5 mg vial + 2.0 mL BAC water = 2.5 mg/mL (0.96 mL = 96 units U-100 per 2.4 mg draw); 10 mg vial + 3.0 mL BAC water = 3.33 mg/mL (0.72 mL = 72 units U-100 per 2.4 mg draw). | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
CJC-1295 Body Composition · Metabolic Health · Sleep · Recovery · Performance Recovery | 100 mcg per injection (1-2 mcg/kg saturation dose) | subcutaneous | 2-3 times daily8-12 weeks | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). |
| Standard: 200 mcg, once daily · Low: 100 mcg, once daily · High: 300 mcg, up to 3x daily | Subcutaneous (SubQ) | 1-3 times daily8-12 weeks · 4-6 weeks off | 10 mg vial with 3 mL bacteriostatic water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: About 30 minutes. The standard dose is 200 mcg, administered once daily. | |
| Non-DAC version referenced at 100-300 mcg (0.1-0.3 mg) per dose due to short half-life. Empty stomach preferred; avoid co-administration with carbohydrates or fats (insulin interference with GH release). | subcutaneous | 1-3x dailyMorning, pre-workout, or before bed · On-cycle 8-12 weeks, off-cycle 6-12 weeks | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
CJC-1295 (DAC) Recovery | Standard: 1,000 mcg once weekly · Low: 500-1,000 mcg once weekly · High: 2,000 mcg once weekly or 1 mg twice weekly | Subcutaneous injection | once weekly8-12 weeks · 8-12 weeks on, 4-6 weeks off | reconstitute lyophilized powder with bacteriostatic water before use | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: 6-8 days. Common research-planning ranges land between 1-2 mg subcutaneously once weekly. |
| DAC version referenced at 2-3 mg per dose; extended half-life supports infrequent dosing. Bedtime administration cited to align with sleep-phase GH release. | subcutaneous | 1-2x weeklyOptionally before bed · On-cycle 8-12 weeks, off-cycle 6-12 weeks | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
CJC-1295 / Ipamorelin (GH Pulse) Recovery · Body Composition · Longevity · Sleep | 200-300 mcg of each peptide (CJC-1295 no DAC and Ipamorelin) daily; lower doses of 100-150 mcg typical for first 2-4 weeks before titration | subcutaneous | Once dailyStandard: 8-12 weeks on, 4 weeks off; Extended: 16 weeks on, 8 weeks off; Short test: 4-6 weeks on, 4 weeks off | For a 20 mg pre-blended vial (10 mg CJC-1295 + 10 mg Ipamorelin): add 3.0 mL bacteriostatic water for a concentration of 6.67 mg/mL total (3.33 mg/mL each peptide); a 200 mcg dose of each peptide = 6 units (0.06 mL) on a U-100 syringe. Alternative fills: 2.0 mL BAC water = 10.0 mg/mL total (5.0 mg/mL each), 200 mcg dose = 4 units (0.04 mL); 2.5 mL BAC water = 8.0 mg/mL total (4.0 mg/mL each), 200 mcg dose = 5 units (0.05 mL). For separate 10 mg vials: add 3.0 mL BAC water to each = 3.33 mg/mL, 200 mcg dose = 6 units (0.06 mL). Step-by-step: inspect the vial; wipe stopper with alcohol prep pad and let dry; draw planned BAC water volume with a sterile syringe; inject BAC water slowly down the inside wall of the vial (do not spray directly onto powder); gently swirl (do not shake) until powder dissolves; label with date and concentration; refrigerate at 35.6-46.4°F (2-8°C) shielded from light; use within 28-30 days; discard if cloudy, discolored, or contaminated. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
CJC-1295 / Ipamorelin (No Dac) Recovery | 200-300 mcg of each peptide daily, typically administered once daily SubQ. | not stated | not stated | Add 3.0 mL BAC water to a 20 mg blend vial. | Peptide Dosing Protocols stack What it saysHide(secondary reference; provider confirmation required). |
DSIP Sleep | Standard: 100-200 mcg · Low: 100 mcg · High: 300 mcg | SubQ | once daily5-7 nights · short course | 2.0 mL bacteriostatic water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). The standard dosing for DSIP is 100-200 mcg subcutaneously once daily. |
| 100-300 mcg subcutaneous; 25 nmol/kg IV (~1.5 mg for 70 kg person) | subcutaneous or intranasal | Once daily before bed; or every 2-3 dayshave not been established. | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
Epitalon Longevity · Sleep · Cognitive Support | Standard: 5 mg/day · High: 10 mg/day | SubQ | 2-3 times per year20 days · short cycle | Add 2.0 mL BAC water to a 10 mg vial. | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: half-life of epitalon? Epitalon clears the bloodstream very quickly, on the order of minutes, whic. The standard dosing for Epitalon is 5 mg per day for 20 days. |
| 5-10 mg per day | subcutaneous or oral | Once daily | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Referenced at 10 mg daily for 10 days followed by a break; longevity stacking contexts cite 2-3 cycles per year. General dosage guideline of 5-10 mg per cycle also referenced. | subcutaneous or nasal | Daily during 10-day cycleEvening cited for sleep-phase cellular repair; morning for circadian alignment · 10-day cycles, 2-3 per year | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
FOXO4-DRI Recovery | Standard: 250 mcg daily · Low: 250 mcg daily · High: 500 mcg daily | SubQ | daily16 weeks · 4 weeks on, 4 weeks off | 3.0 mL BAC water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Standard dosing starts at 250 mcg daily and increases to 500 mcg daily. |
GHK-Cu Tissue Repair · Inflammation · Longevity · Recovery · Post-Procedure Recovery | Standard: 1.0-1.5 mg · Low: 1.0 mg · High: 2.0 mg | Subcutaneous injection | Daily4-6 weeks · 4-8 weeks | 50 mg vial reconstituted with 2.0 mL bacteriostatic water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). The standard dosing for GHK-Cu is 1.0-1.5 mg daily for 4-6 weeks. |
| 1-2 mg SC daily, or topical application | subcutaneous or topical | once daily30-day cycles | Commonly 50 mg vials (injectable) or topical formulationsReconstitute with bacteriostatic water (injectable) | Commonly published practitioner dosing range - provider confirmation required. | |
| Topical: 0.01-1% in cream/serum; SC injection: 1-2 mg daily | subcutaneous or oral or topical | Topical: once or twice daily; SC: once dailyRepeatable | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Topical: serum to face and neck twice daily (AM and PM) after cleansing, before moisturizer. Injectable referenced at 200-300 mcg (0.2-0.3 mg) before bedtime in recovery contexts; sterile technique and supervision stressed. Microneedling before topical cited to enhance absorption. | topical or subcutaneous | Topical 2x daily; injectable nightly in recovery contextsTopical AM/PM; injectable before bed | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
GHRP-6 Recovery | Standard: 300 mcg · Low: 100 mcg · High: 300 mcg | SubQ | 3x daily, at least 4 hours apartnull · 8 weeks on, 4 weeks off | 3 mL bacteriostatic water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: null. GHRP-6 is typically dosed at 100-300 mcg per injection. |
| Cycling reference: 6-8 weeks on, 4 weeks off. Cited for appetite stimulation and GH release with fat metabolism support. | subcutaneous | not statedOn-cycle 6-8 weeks, off-cycle 4 weeks | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
GLOW Tissue Repair · Skin & tissue · Soft Tissue Recovery · Recovery | Pre-blend: 0.10 mL (10 units) daily = ~2.33 mg total blend (~1.67 mg GHK-Cu, ~0.33 mg TB-500, ~0.33 mg BPC-157). Separate vials: BPC-157 250-500 mcg/day; TB-500 2.5-5 mg per injection 2x/week (loading), 2 mg per injection (maintenance); GHK-Cu 1-2 mg/day (loading), 1 mg/day (maintenance). | subcutaneous | Once daily (pre-blend); separate vials: BPC-157 daily, TB-500 twice weekly, GHK-Cu dailyStandard: 4-6 weeks on, 2-4 weeks off; Extended: 8-12 weeks on, 4-8 weeks off; Skin-focused blend: 4 weeks on, 2-4 weeks off. GHK-Cu copper cycling typically governs cycle length: 30-60 days on, equal time off. | Pre-blend (70 mg vial): Add 3.0 mL bacteriostatic water → ~23.3 mg/mL total blend; standard daily dose is 0.10 mL (10 units) = ~2.33 mg total. Separate vials, BPC-157 5 mg vial: add 2 mL BAC water → 2,500 mcg/mL; BPC-157 10 mg vial: add 2 mL BAC water → 5,000 mcg/mL. TB-500 5 mg vial: add 1 mL BAC water → 5 mg/mL; TB-500 10 mg vial: add 2 mL BAC water → 5 mg/mL. GHK-Cu 50 mg vial: add 5 mL BAC water → 10 mg/mL; GHK-Cu 100 mg vial: add 10 mL BAC water → 10 mg/mL. Standard steps: wipe stopper with alcohol swab and let dry; draw planned BAC water volume; aim water at inside of glass wall, not directly onto powder; let water flow slowly down vial wall; roll gently 30-60 seconds until dissolved (do not shake); inspect for clarity (GHK-Cu may show slight blue/green tint from copper; BPC-157 and TB-500 should be clear); label with reconstitution date and store at 2-8 °C (35.6-46.4 °F). TB-500 is the limiting reconstitution-stability window, most workflows use the reconstituted blend within 1-2 weeks. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
| 10 units (0.10 mL) daily, approximately 2.33 mg total blend. | not stated | not stated | Add 3.0 mL bacteriostatic water to reconstitute. | Peptide Dosing Protocols stack What it saysHide(secondary reference; provider confirmation required). | |
Glutathione Immune Support · Inflammation · Longevity · Metabolic Health · Recovery | Standard: 250-1,000 mg/day · Low: 250 mg/day · High: 1,000 mg/day | Oral | daily4 weeks - 6 months · 4 weeks or longer to appear and faded after stopping. | reconstitution and supplies for injectable use, side effects, and where the evidence stops. | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Standard oral dosing ranges from 250 to 1,000 mg per day. |
| 200-600 mg per injection (IM/SC); 600-1400 mg per session (IV push); 500-1000 mg daily (oral) | subcutaneous or intranasal or oral or topical or intramuscular | 1-3 times per week (injectable); daily (oral)Key limitations / notes | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
HCG Recovery | 250-500 IU per injection (TRT adjunct); 1500-5000 IU (fertility protocols) | subcutaneous or oral or topical or intramuscular | Every other day or 2-3 times per week | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). |
Humanin Recovery | Standard: 4 mg/kg · Low: 2.5 mg/kg/injection | IP | 2x/week4-12 weeks · 6-8 weeks | reconstituted with 2 mL bacteriostatic water (10 mg/mL) | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). The standard dosing for Humanin is 4 mg/kg administered via intraperitoneal injection twice weekly. |
IGF-1 LR3 Recovery | Standard: 40 mcg/day · Low: 20 mcg/day · High: 100 mcg/day | Subcutaneous (SubQ) or intramuscular (IM) injection | Once daily4 weeks · 4 weeks on, 4 weeks off | reconstituted in 2 mL of bacteriostatic water (500 mcg/mL) | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: 20-30 hours. Standard dosing is 40 mcg/day. |
Ipamorelin Sleep · Body Composition · Recovery · Performance Recovery · Longevity | Standard: 200-300 mcg/day · Low: 100 mcg/day · High: 300 mcg | subcutaneous | 1-3 times per day8-12 weeks on, then 4 weeks off · 8-12 weeks | 3.0 mL BAC water for 10 mg vial | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: about two hours. Most research protocols use 100 to 300 mcg per shot, one to three times per day. |
| 200-300 mcg per injection | subcutaneous | not stated8-12 weeks, then 2-4 weeks off · Repeatable | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Referenced at 100-300 mcg (0.1-0.3 mg) per dose. Commonly paired with CJC-1295 for synergistic GH release with minimal cortisol or prolactin elevation. Sample stacks cite 100 mcg each, fasted morning and before bed. | subcutaneous | 2-3x daily (vitality contexts cite once daily)Morning fasted, pre-workout, or before bed · On-cycle 8-12 weeks, off-cycle 4 weeks | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
Kisspeptin-10 Recovery | Standard: 100-200 mcg · Low: 50-100 mcg | Subcutaneous (SC) | Once daily SC8 weeks: 56 doses needed; one vial still leaves margin for losses and schedule adjustments Insulin Syringes (U-100, 0. | Reconstitute with bacteriostatic water (BAC water) before drawing any dose. | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: about 4 minutes. The standard dosing for Kisspeptin-10 is 100-200 mcg once daily. |
| 9.6 nmol/kg SC (IVF trigger); 1 nmol/kg IV (diagnostic challenge) | subcutaneous | Single dose (IVF trigger); single dose (diagnostic)Single administration per IVF · Repeatable | Sterile water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
KLOW Tissue Repair · Skin & tissue · Gut Health · Inflammation · Recovery | ~6.0 mg total blend per day (22.5 units / 0.225 mL at 3.0 mL reconstitution) at maintenance phase; titration starts at ~2.0 mg total blend (7.5 units) and steps up to ~4.0 mg (15 units) then ~6.0 mg (22.5 units) | subcutaneous | Once dailyStandard: 4-6 weeks on, 2-4 weeks off; Extended: 8-12 weeks on, 4 weeks off; Maximum extension: up to 16 weeks on, 4+ weeks off (no safety data supports continuous use beyond 12 weeks) | Add 3.0 mL bacteriostatic water to the 80 mg vial to yield ~26.7 mg/mL total blend concentration. Steps: (1) Inspect the vial, check label, batch, and powder appearance; a discolored or damp vial should not be used. (2) Sanitize, swab the rubber stopper of the KLOW vial and the bacteriostatic water vial with alcohol prep pads and let dry. (3) Draw 3.0 mL bacteriostatic water with a sterile syringe; vent the BAC water vial if needed. (4) Inject down the vial wall, insert the needle and inject BAC water slowly down the inside wall; avoid spraying directly onto the powder to prevent foaming and denaturation. (5) Swirl, do not shake, gently swirl or roll until powder is fully dissolved; solution should be clear with possible light blue tint from GHK-Cu (normal). (6) Label with reconstitution date and store at 35.6-46.4°F (2-8°C), protected from light. (7) Use within 14-28 days when refrigerated; avoid freeze-thaw cycles. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
| Commonly, a once-daily subcutaneous injection is used, with a typical cycle of 4-6 weeks on and 2-4 weeks off. | not stated | not stated | Add 3.0 mL of bacteriostatic water to the 80 mg vial. | Peptide Dosing Protocols stack What it saysHide(secondary reference; provider confirmation required). | |
KPV Inflammation · Gut Health · Tissue Repair · Recovery | Standard: 200-500 mcg once or twice daily · Low: 200 mcg/day SubQ · High: 500 mcg twice daily | oral, subcutaneous | once or twice dailyWeeks 1-8+ · 4-8 weeks on, 2-4 weeks off | 2 mL BAC water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). KPV is commonly dosed at 200-500 mcg once or twice daily for gut health. |
| 200-500 mcg SC daily, or 250-500 mcg orally twice daily for gut-directed support | subcutaneous or oral | once daily (SC) or twice daily (oral)4-8 weeks · 4-8 week cycles | Commonly 5 mg vials (injectable) or oral capsulesReconstitute with bacteriostatic water (injectable form) | Commonly published practitioner dosing range - provider confirmation required. | |
| 200-500 mcg per injection (SC); or oral capsules as directed | subcutaneous or oral | Once daily (SC); 1-2 times daily (oral) | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
LL-37 Immune Support · Inflammation · Gut Health · Tissue Repair | 100 mcg SC daily or every other day | subcutaneous | daily or every other day2-4 weeks · Short cycles; reassess | Commonly 5 mg vialsReconstitute with bacteriostatic water | Commonly published practitioner dosing range - provider confirmation required. |
| 100-200 mcg daily (SC); topical per formulation | subcutaneous or oral or topical | Once daily, 5 days per week (SC); as directed (topical)2-4 weeks, then 2 weeks off · Repeatable | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
Mazdutide Metabolic Health · Body Composition · Weight Management · Appetite Regulation | 2.5-5 mg | subcutaneous | Once weeklyTitrate over weeks per tolerance | 10 mg vial10 mg vial + 3.0 mL bacteriostatic water (~3.33 mg/mL). Draw 3.0 mL BAC water, inject slowly down the vial wall, swirl gently (do not shake), refrigerate at 2-8 C protected from light. | Peptide Dosages - What it saysHide(secondary reference; provider confirmation required). Educational protocol, mirrors clinical-trial gradual titration. [Source: Peptide Dosages] |
Melanotan I (MT-1) Recovery | 0.16 mg/kg daily (injection protocol); 16 mg implant every 2 months (approved) | subcutaneous or oral | Daily for 10 days per10-day injection | Sterile water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). |
Melanotan II (MT-2) Recovery | Loading: 0.25-0.5 mg daily; Maintenance: 0.5-1.0 mg 1-2 times per week | subcutaneous or oral | Daily during loading (1-3 weeks); 1-2 times per week for maintenanceLoading: 2-4 weeks; Maintenance: ongoing as desired | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). |
| Standard: 500-1000 mcg daily · Low: 100-250 mcg daily · High: 250-500 mcg daily | Subcutaneous (SubQ) injection | 1-2x per week4-6 weeks · 6 weeks | 2 mL BAC water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: half-life Melanotan 2 ~1-2 hours Afamelanotide(MT-I) ~0. The standard loading dose is 500-1000 mcg daily. | |
Methylene Blue Recovery | Standard: 1 mg/kg · Low: 5-20 mg/day · High: 10 mg/kg | IV, Oral | not stated | no | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Methylene blue is typically dosed at 1 mg/kg for methemoglobinemia. |
MOTS-c Metabolic Health · Longevity · Performance Recovery · Recovery | Standard: 5 mg · Low: 5 mg · High: 10 mg | Subcutaneous injection | 2 to 3 times per week4 to 8 weeks · 4-6 weeks | Reconstitute a 10 mg vial with 1.0 mL bacteriostatic water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). The standard dosing is 5 mg subcutaneously, 3 times per week for 4-6 weeks. |
| 5-10 mg SC 2-3 times weekly | subcutaneous | 2-3 times weekly4 weeks · 4-week cycles | Commonly 10 mg vialsReconstitute with bacteriostatic water | Commonly published practitioner dosing range - provider confirmation required. | |
| 5-10 mg per injection | subcutaneous | 2-3 times per week or every 5 days | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Referenced at 10 mg weekly in divided doses within longevity stacking. Morning administration cited for circadian and mitochondrial alignment. | subcutaneous | Weekly total (10 mg), divided dosesMorning · Cycle every few months in longevity contexts | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
NAD+ Longevity · Metabolic Health · Cognitive Support · Recovery | Standard: 100 mg · Low: 50 mg · High: 200 mg | SubQ | 2-3x weekly4-8 weeks · 4 weeks, then escalate to 100 mg weekly. | 7.5 mL BAC water for 750 mg vial | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). The standard dose for NAD+ is 100 mg administered 2-3 times weekly. |
| 250-750 mg per IV session; 300-1000 mg daily for oral precursors (NR/NMN) | oral | 1-2x weekly IV (loading), monthly (maintenance); daily oral4-8 week loading phase IV; ongoing for oral precursors | Normal saline (0.9% NaCl) 250-500 mL for IV | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
Oxytocin Acetate Recovery | Standard: 200-300 mcg · Low: 100 mcg · High: 400-500 mcg | Subcutaneous | Once dailycycle Duration 1-2 weeks Review Point Week 2 Notes Used in mood, anxiety, and pain research blocks. | add 2-3 mL bacteriostatic water to a 2 mg or 5 mg lyophilized vial | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: about 3-6 minutes. The standard dosing for subcutaneous oxytocin is 200-300 mcg once daily. |
| 24 IU intranasal (6 sprays of 4 IU each, 3 per nostril) | intranasal | Once or twice daily for research protocolsnonapeptide neurohormone produced in the h | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
P21 Recovery | Practitioner ranges vary; commonly ~1 mg SC daily - provider-directed | subcutaneous | once dailyPer provider direction | Compounded; variesReconstitute with bacteriostatic water | Commonly published practitioner dosing range - provider confirmation required. |
Pinealon Recovery | Standard: 1.0 to 2.0 mg per day · Low: 1.0 mg · High: 2.0 mg | subcutaneous injection or oral | Once daily10 to 20 days · 2 to 3 cycles per year | 3.0 mL BAC water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Pinealon is typically dosed at 1.0 to 2.0 mg per day. |
PT-141 Recovery | Standard: 1.75 mg | Subcutaneous (abdomen or thigh) | 1 dose per 24 hours8 doses per month | reconstitution math, route considerations, and side effects for this bremelanotide peptide. | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). The standard dose of PT-141 is 1.75 mg subcutaneous at least 45 minutes before sexual activity. |
| 1.75 mg | subcutaneous or oral | not stated | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Injection referenced at 0.5-2 mg per dose with onset in 1-4 hours, peak at 6-12 hours, duration 24-72 hours. Nasal spray referenced at 2-4 sprays per nostril, onset 30-60 minutes, duration 6-12 hours. Start low; side effects are dose-dependent (nausea most common). | subcutaneous or nasal | As neededOn-demand, 1-4 hours before desired effect (injection) | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
Retatrutide Metabolic Health · Body Composition · Weight Management · Appetite Regulation | Standard: 1 mg titrating to 12 mg once weekly (Phase 3 TRIUMPH: 1 mg → 2 mg → 4 mg → 6 mg → 9 mg → 12 mg, stepping up every 4 weeks) · Low: 1 mg once weekly · High: 12 mg once weekly | Subcutaneous injection | Once per week, on the same day each week48 weeks (Phase 2 reference); 68-72 weeks (Phase 3 TRIUMPH reference) · Every 4 weeks at each dose step; review at 4 mg, 9 mg, 12 mg; slow titration option adds 2-4 weeks per dose step when GI symptoms persist | 10 mg vial with 2.0 mL BAC water yields a concentration of 5 mg/mL; use U-100 insulin syringes | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Retatrutide is dosed once weekly via subcutaneous injection starting at 1 mg and titrating up every 4 weeks to a maximum of 12 mg following the Phase 3 TRIUMPH schedule. |
| 1-12 mg | subcutaneous | Once weeklyAny time of day · Titrate over weeks per response/tolerance | not stated | Reference titration range, provider confirm | |
Retatrutide / MOTS-c Metabolic Health · Body Composition · Weight Management · Mitochondrial Function | Retatrutide: titrate 1 → 2 → 4 → 6 → 9 mg weekly (maintenance 9 mg or 12 mg weekly); MOTS-c intermittent: 5 mg 2-3x weekly (maintenance 5-10 mg 2-3x weekly); MOTS-c low-dose daily alternative: start 200 mcg/day up to 1 mg/day | subcutaneous | Retatrutide: once weekly; MOTS-c: 2-3x weekly (intermittent) or daily (low-dose alternative)Conservative starter: retatrutide weeks 1-24, MOTS-c weeks 5-12 then off; Standard research cycle: retatrutide weeks 1-48, MOTS-c 8-week pulses with 4-week breaks; Aggressive deficit: retatrutide weeks 1-68, MOTS-c 6 weeks on / 2 weeks off repeating | Standard 7-Step Reconstitution: (1) Let the lyophilized vial and BAC water reach room temperature before opening. (2) Swab both vial stoppers with alcohol and let them dry. (3) Pull the planned BAC water volume into a sterile syringe. (4) Inject the BAC water slowly down the inside of the vial wall, do not aim at the powder. (5) Swirl or roll gently until fully dissolved; do not shake. (6) Confirm the solution is clear; label the vial with compound name, concentration, and date. (7) Store at 2-8 °C; use retatrutide within 28-60 days and MOTS-c within 7 days for best potency. Each compound is reconstituted separately. Retatrutide common concentration: 10 mg vial + 1.0 mL BAC water = 10 mg/mL. MOTS-c common concentration: 10 mg vial + 2.0 mL BAC water = 5 mg/mL. MOTS-c aliquots may be stored at -20 °C for 2-3 months. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
RT3 Recovery | Standard: 1 mg once weekly · Low: 1 mg · High: 12 mg | Subcutaneous injection | once per weeknull | null | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: null. The standard dosing starts at 1 mg once weekly and titrates up to 12 mg. |
| 0.5 mg starting dose, escalating to target of 8-12 mg | subcutaneous or oral | Once weeklyKey Question | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
Russian Nootropic Stack Cognitive Function · Longevity · Neuroprotection | Semax: 300-800 mcg/day (SubQ), 400-600 mcg/day (intranasal); Selank: 250-500 mcg/day (SubQ), 400-750 mcg/day (intranasal). Maintenance example: Semax 600 mcg + Selank 400 mcg daily. | Subcutaneous injection or intranasal (drops/spray) | Once daily (SubQ, morning before 2 PM); 2x daily for Semax intranasal (AM + early afternoon); 2-3x daily for Selank intranasalStandard cycle: 4 weeks on / 4 weeks off; Short intensive: 10-14 days on / 10-14 days off; Extended: 8 weeks (5 days/week) / 4 weeks off; Clinical intranasal reference: 14-21 days on / 14-21 days off | Each compound is reconstituted separately using bacteriostatic water (BAC water). For a 10 mg vial: add 3.0 mL BAC water to reach 3,333 mcg/mL, or 2.0 mL to reach 5,000 mcg/mL. For a 5 mg vial: add 2.0 mL BAC water to reach 2,500 mcg/mL, or 1.0 mL to reach 5,000 mcg/mL. Use 0.3 mL / 30-unit insulin syringes for accuracy at small volumes. Label each vial with compound name, concentration, and reconstitution date. Semax is light-sensitive (contains methionine, which oxidizes when exposed to light); wrap the reconstituted vial in aluminum foil or store in a dark container. Both vials are stable for approximately 30 days at 2-8 °C once reconstituted. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
Selank Neuroinflammation · Sleep | Standard: 250-500 mcg per day · Low: 250 mcg · High: 500 mcg | Subcutaneous injection (SubQ) or intranasal nasal spray | once daily for SubQ; 14-21 days for intranasal4 weeks for SubQ; 14-21 days for intranasal · 4 weeks on, 4 weeks off for SubQ; 1-3 weeks off for intranasal | 3 mL, 6 mL, or 10 mL per 30 mg vial | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: Half-life Selank ~2-10 min plasma; 12-24 hr functional duration Semax ~3-5 min plasma; 20-24. The standard research-use SubQ schedule is 4 weeks on at 250-500 mcg per day. |
| 250-500 mcg intranasally daily (or 0.15% solution per protocol) | intranasal | once or twice daily10-14 day cycles · Repeat cycles per provider direction | Compounded intranasal solution/sprayCompounded intranasal solution - no reconstitution required | Commonly published practitioner dosing range - provider confirmation required. | |
| 300-600 mcg per dose intranasal; 200-400 mcg per dose subcutaneous | subcutaneous or intranasal or oral | 2-3 times daily (intranasal); once daily (SC, 5 days per week)30 days on, 30 days off; approximately 6 | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Referenced at 250-500 mcg (0.25-0.5 mg) per dose. Nasal spray cited as the most common route; onset within 30-60 minutes, peak benefit after several days of consistent use. | nasal or subcutaneous | Nasal 1-3x daily; injection once daily or as needed | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
Semaglutide Metabolic Health · Body Composition · Weight Management · Appetite Regulation | Standard: 2.4 mg · Low: 0.25 mg · High: 2.4 mg | subcutaneous injection | once weekly16 weeks · 16 weeks on, ongoing weekly maintenance | reconstituted lyophilized vial | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: about 7 days. Standard dosing escalates to 2.4 mg over 16 weeks. |
Semax Neuroinflammation | Standard: 0.6 to 1.5 mg/day · Low: sub-milligram per administration · High: up to ~1 mg/kg | Intranasal solution, Subcutaneous injection | Daily administration, often divided into morning and afternoon doses10-14 days for standard short course, 4-6 weeks for extended cognitive course · 4-6 weeks on, 2-4 weeks off | Requires reconstitution with bacteriostatic water before subcutaneous research use | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Standard dosing for Semax is about 0.6 to 1.5 mg per day, typically split into two administrations. |
| 300-600 mcg intranasally daily (or 1-3 drops/nostril of 0.1% solution) | intranasal | once or twice daily10-14 day cycles · Repeat cycles per provider direction | Compounded intranasal solution/sprayCompounded intranasal solution - no reconstitution required | Commonly published practitioner dosing range - provider confirmation required. | |
| 200-600 mcg per dose (0.1% solution) for nootropic use; 3-6 mg per dose (1% solution) for stroke | intranasal | 2-3 times dailyRepeatable | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Referenced at 300-600 mcg (0.3-0.6 mg) daily in brain health protocols. Morning administration cited to carry cognitive benefit through the day. Rotation with other nootropic peptides between cycles referenced to maintain response. | nasal | DailyMorning · 4 weeks on with rotation between cycles | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
Sermorelin Acetate Longevity · Sleep · Body Composition · Metabolic Health · Recovery | Standard: 200-300 mcg · Low: 100 mcg · High: 400-500 mcg | subcutaneous injection | nightly3-6 months · Cycle length Planning note 4 weeks 1 vial 28 nights of 200 mcg from one vial. | 3 mL bacteriostatic (BAC) water in a 10 mg vial gives 3 units per 100 mcg on a U-100 insulin syringe. | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: 11-12 minutes. Common dose is 200-300 mcg subQ nightly. |
| 200-300 mcg | subcutaneous or oral | Once daily at bedtime, 5 nights per week3-6 months | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
SLU-PP-322 Recovery | Standard: 50 mg (1 tablet) · Low: ≤1.5 mg · High: 100 mg (2 tablets) | oral | once daily6 weeks IP dosing (Burris-lab standard) Improved ejection fraction; reduced fibrosis; increased survival in the TAC model. | 5 mg vial reconstituted with 2 mL BAC water (2,500 mcg/mL) and a daily 500 mcg subcutaneous draw, a common community pattern, not a clinically validated dose. | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: half-life, there is no validated missed-dose rule. The standard dosing for SLU-PP-332 is 50 mg taken once daily. |
SNAP-8 Recovery | 3-10% concentration in formulation (solution, not pure peptide) | topical | Twice daily (morning and evening)Continuous use; minimum 28 days for measurable results | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). |
SS-31 Mitochondria | 40 mg subcutaneous daily (Phase 3 dose); or 5-10 mg daily (research community range) | subcutaneous | Once dailyRepeatable | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). |
| Standard: 40 mg · Low: 20 mg | Subcutaneous | once daily12 weeks per period Open-label extension All remaining patients on elamipretide 40 mg SC daily Up to 168 weeks Reported in Genetics in Medicine, 2024. | reconstitution, and safety considerations for this mitochondria-targeted peptide. | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). The standard dosing for SS-31 is 40 mg subcutaneously once daily. | |
| Investigational; commonly studied at 40 mg SC daily - provider-directed | subcutaneous | once daily (study protocols)Per provider/study protocol | Compounded; variesReconstitute per compounding pharmacy instructions | Commonly published practitioner dosing range - provider confirmation required. | |
Survodutide Recovery | Standard: 4.8 mg once weekly · Low: 0.6 mg once weekly · High: 4.8 mg once weekly | Subcutaneous injection | once weekly76 weeks · null | 1.0 to 2.0 mL per vial | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: null. Survodutide is administered at a standard dose of 4.8 mg once weekly. |
TA1 Immune Support · Inflammation · Recovery · Post-Procedure Recovery | Standard: 1.6 mg | Subcutaneous | Twice weekly6 to 12 months · 12 weeks Community-derived, not from a clinical trial These durations are reported from research, not personal-use recommendations. | 2 mL bacteriostatic water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: half-life of about 2-3 hours. The standard dosing for TA1 is 1.6 mg subcutaneously twice weekly. |
| 1.5 mg SC twice weekly, or 450-900 mcg daily | subcutaneous | twice weekly, or daily4-12 weeks · Repeat course per provider direction | Commonly 5 mg or 10 mg vialsReconstitute with sterile/bacteriostatic water | Commonly published practitioner dosing range - provider confirmation required. | |
| 1.6 mg | subcutaneous or oral | Twice weekly (standard); daily during chemotherapy | Sterile water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Cycling reference for immune support: 6-12 weeks on, 6 weeks off. | subcutaneous | not statedOn-cycle 6-12 weeks, off-cycle 6 weeks | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
TB-500 / TB4 Tissue Repair · Soft Tissue Recovery · Tendon/Ligament Recovery · Injury Recovery · Performance Recovery · Recovery | Standard: 2-2.5 mg subcutaneous twice weekly · Low: 2 mg twice weekly · High: 2.5 mg subcutaneous once weekly | subcutaneous injection | twice weekly for loading, once weekly for maintenanceWeeks 1-6 for loading, Weeks 7-12 for maintenance · 4-12 weeks | 2.0 mL bacteriostatic water for 10 mg vial | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). TB-500 is commonly dosed at 2-2.5 mg subcutaneously twice weekly during the loading phase. |
| 2-2.5 mg SC twice weekly (loading 4-6 weeks), then 2 mg weekly maintenance | subcutaneous | twice weekly (loading), then weekly4-6 week loading, then maintenance · Loading phase then maintenance phase | Commonly 5 mg or 10 mg vialsReconstitute with bacteriostatic water | Commonly published practitioner dosing range - provider confirmation required. | |
| 2-2.5 mg per injection (loading); 750 mcg-2 mg (maintenance) | subcutaneous or oral or topical | not stated | Bacteriostatic water | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Referenced with a loading phase of 5-10 mg weekly for 4-6 weeks, then maintenance at 2-5 mg weekly split into smaller doses. Results typically noticed within 2-4 weeks. Caution flag: angiogenesis-promoting, so cancer or tumor history warrants medical consultation first. | subcutaneous or intramuscular | Weekly total (2-10 mg) split into smaller dosesPost-workout or before bed · On-cycle 4-6 weeks, off-cycle 1-2 months | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
Tesamorelin Metabolic Health · Body Composition · Cognitive Support | Standard: 2 mg once a day | Subcutaneous injection in the abdomen only | Once daily26 weeks · Cycle length Planning note 4 weeks 6 vials (10 mg) 28 daily doses needed. | Reconstitute with bacteriostatic water | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: Half-Life Tesamorelin 26-38 minutes Sermorelin 11-12 minutes CJC-1295(DAC) ~6-8 days Fe. The standard dosing for Tesamorelin is 2 mg administered once daily. |
| 1-2 mg SC daily at bedtime | subcutaneous | once daily at bedtime12+ weeks · Continuous per provider direction | Commonly 2 mg vialsReconstitute with sterile/bacteriostatic water | Commonly published practitioner dosing range - provider confirmation required. | |
| 2 mg | subcutaneous | Once daily | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
| Fat loss stacking reference: 200 mcg (0.2 mg) fasted morning paired with AOD-9604 300 mcg. Cited for visceral fat targeting with Mod GRF 1-29 as a pulse-enhancing partner. | subcutaneous | Daily in stack contextsMorning, fasted | not stated | Peptide Therapy Reference Text, internal KB v4 What it saysHide(Aug 2026), secondary reference; provider confirmation required. | |
Tesamorelin / Ipamorelin Body Composition · Metabolic Health · Recovery · Longevity | Tesamorelin 1-2 mg + Ipamorelin 200-300 mcg (separate vials); or blend draws of 10-40 units/day depending on vial ratio (5/5 vial example: up to 667 mcg tesamorelin + 667 mcg ipamorelin at 40 units) | subcutaneous | Once daily subcutaneousStandard: 8-12 weeks on, 4-8 weeks off; Extended: 12-16 weeks on, 4-8 weeks off; typical cycle 8-16 weeks | Add 3.0 mL bacteriostatic water to the 3 mL vial, aiming the stream down the inside vial wall; swirl gently (do not shake) until fully dissolved. Inspect: solution should be clear; discard if cloudy or full of particles. Label with ratio, date, and concentration. Refrigerate at 2-8°C (35.6-46.4°F), protected from light. 10/3 vial yields ~4.33 mg/mL total (3.33 mg/mL tesamorelin + 1.0 mg/mL ipamorelin); 5/5 vial yields ~3.33 mg/mL total (1.67 mg/mL each). Do not freeze reconstituted solution. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
Tesofensine Recovery | Standard: 0.5 mg once daily · Low: 0.25 mg once daily | Oral tablet | once daily24 weeks · 24 weeks on | not stated | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: about 9 days. The standard dosing for tesofensine is 0.5 mg taken once daily. |
Tirzepatide Metabolic Health · Body Composition · Weight Management · Appetite Regulation | 2.5-15 mg | subcutaneous | Once weeklyAny time of day · Titrate over weeks per response/tolerance | not stated | Reference titration range, provider confirm |
| Standard: 5 mg, 10 mg, or 15 mg once weekly (three approved maintenance doses) · Low: 2.5 mg once weekly · High: 15 mg once weekly | Subcutaneous injection | Once weeklyWeeks 1-4 at 2.5 mg, stepping up every 4 weeks; full ladder to 15 mg reached at week 21+ · 4 weeks (Phase 1, 2.5 mg), 8 weeks (through 5 mg), 12 weeks (through 7.5 mg), 16 weeks (through 10 mg), 24 weeks (full ladder to 15 mg) | 40 mg vial + 2.0 mL BAC water = 20 mg/mL; reconstituted solution keeps for ~28 days refrigerated | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: 5 days. Tirzepatide is titrated once weekly from 2.5 mg up to a maximum of 15 mg in 2.5 mg increments every 4 weeks via subcutaneous injection. | |
TRZ Recovery | Standard: 5 mg once weekly · Low: 2.5 mg once weekly · High: 15 mg once weekly | Subcutaneous injection | once weeklyCycle length Planning note 4 weeks (Phase 1, 2. | 2.0 mL BAC water for a 40 mg vial | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: 5 days. Tirzepatide is administered once weekly, starting at 5 mg. |
| 2.5 mg starting dose, escalating to 5-15 mg maintenance | subcutaneous or oral | Once weeklyOngoing (chronic therapy) | not stated | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). | |
VIP Immune · Neuroinflammation | 50 mcg per spray, 4-8 sprays daily (CIRS/nasal); 50-150 pmol/kg/min (IV infusion) | intranasal or oral | not stated | Sterile 0.9% saline | Peptide Protocol Wiki What it saysHide(secondary reference; provider confirmation required). |
| Standard: 100 mcg · Low: 50 mcg · High: 200 mcg | SubQ | 1-2x dailyOngoing · 12 week cycles. | A 10 mg subcutaneous vial with 3 mL bacteriostatic water gives about 3.33 mg/mL. | Peptide Dosing Protocols What it saysHide(secondary reference; provider confirmation required). Half-life: very short. The standard dosing for VIP is 100 mcg taken 1-2 times daily. | |
| 50 mcg per spray intranasally, up to 4 times daily (titrate per CIRS protocol; typically after correcting other abnormalities) | intranasal | up to 4 times dailyPer provider direction | Compounded intranasal spray (e.g. 50 mcg/actuation)Compounded intranasal spray - no reconstitution required | Commonly published practitioner dosing range - provider confirmation required. | |
Vladonix Recovery | 1-2 capsules daily (commonly 2 capsules daily) | oral | once or twice daily20-30 day course · Repeat course 1-2x per year | Oral capsules (peptide bioregulator)Not applicable (oral capsule) | Commonly published practitioner dosing range - provider confirmation required. |
Wolverine Tissue Repair · Soft Tissue Recovery · Injury Recovery · Recovery | Pre-blended: 0.5-2.0 mg total blend daily (0.25-1.0 mg BPC-157 + 0.25-1.0 mg TB-500); Separate vials: BPC-157 250-500 mcg daily, TB-500 2.0-5.0 mg 2x/week (loading), TB-500 2.0 mg 1-2x/week (maintenance) | subcutaneous | Pre-blended: daily; Separate vials: BPC-157 daily, TB-500 2x/week (loading) or 1-2x/week (maintenance)6-12 weeks total; loading phase weeks 1-4, maintenance phase weeks 5-8 or 5-12 depending on protocol; off-cycle gaps of 2-4 weeks commonly described | Pre-blended 20 mg vial: Add 2.0 mL bacteriostatic water → 10 mg/mL total (5 mg/mL each compound); 10 units (0.10 mL) delivers 0.5 mg BPC-157 + 0.5 mg TB-500; ~20 doses per vial at 1.0 mg/day. Separate vials: Add 2.0 mL BAC water to each 10 mg vial → 5.0 mg/mL each. Steps: allow lyophilized peptide to reach room temperature; wipe both vial stoppers with alcohol swabs; draw planned BAC water volume into sterile syringe; inject BAC water against inside wall of peptide vial slowly, never directly onto powder; swirl gently until fully dissolved, do not shake; verify solution is clear (TB-500 may appear very faintly tinted); refrigerate at 35.6-46.4°F (2-8°C) and use within supplier's stated beyond-use window. | peptidedosingprotocols.com What it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
| 1.0 mg total blend daily (0.5 mg of each compound) from a pre-blended 20 mg vial. | not stated | not stated | Reconstitute with 2.0 mL BAC water for a final concentration of 10 mg/mL total blend (5 mg/mL each component). | Peptide Dosing Protocols stack What it saysHide(secondary reference; provider confirmation required). |